VismoHisto

Published: 5 December 2019| Version 1 | DOI: 10.17632/wsdgt4cf8y.1
Contributors:
Scott Fosko, Melinda Chu, Eric Armbrecht, Tim Galperin, Geoffrey Potts, Adam Mattox, Anastasia Kurta, Kristen Polito, Jordan Slutsky, Nicole Burkemper, M. Yadira Hurley

Description

Supporting data for JAAD manuscript entitled: Efficacy, rate of tumor response, and safety of a short course (12-24 weeks) of oral vismodegib in various histologic subtypes (infiltrative, nodular and superficial) of high risk and/or locally advanced basal cell carcinoma, in an open label prospective case series clinical trial.

Files

Institutions

  • Saint Louis University School of Medicine

Categories

Oncology, Pathology, Basal Cell Carcinoma, Vismodegib, Histopathology, Non-Melanoma Skin Cancer, Hedgehog

Licence